Detalhe da pesquisa
1.
Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial.
Lancet Oncol
; 25(1): 99-107, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043558
2.
[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial.
Lancet Oncol
; 25(5): 563-571, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38621400
3.
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial.
Lancet Oncol
; 24(4): 323-334, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36990608
4.
PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial.
Lancet Oncol
; 23(11): 1389-1397, 2022 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-36261050
5.
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial.
Lancet
; 397(10276): 797-804, 2021 02 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33581798
6.
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer.
N Engl J Med
; 381(2): 121-131, 2019 07 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31157964
7.
Combined impact of lipidomic and genetic aberrations on clinical outcomes in metastatic castration-resistant prostate cancer.
BMC Med
; 20(1): 112, 2022 03 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-35331214
8.
ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
BJU Int
; 128(5): 642-651, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34028967
9.
An analysis of a multiple biomarker panel to better predict prostate cancer metastasis after radical prostatectomy.
Int J Cancer
; 144(5): 1151-1159, 2019 03 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30288742
10.
TheraP: a randomized phase 2 trial of 177 Lu-PSMA-617 theranostic treatment vs cabazitaxel in progressive metastatic castration-resistant prostate cancer (Clinical Trial Protocol ANZUP 1603).
BJU Int
; 124 Suppl 1: 5-13, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31638341
11.
Pembrolizumab with Chemoradiation as Treatment for Muscle-invasive Bladder Cancer: Analysis of Safety and Efficacy of the PCR-MIB Phase 2 Clinical Trial (ANZUP 1502).
Eur Urol Oncol
; 2023 Oct 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-37806844
12.
Distributed information encoding and decoding using self-organized spatial patterns.
Patterns (N Y)
; 3(10): 100590, 2022 Oct 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-36277815
13.
Modulation of Plasma Lipidomic Profiles in Metastatic Castration-Resistant Prostate Cancer by Simvastatin.
Cancers (Basel)
; 14(19)2022 Sep 30.
Artigo
em Inglês
| MEDLINE | ID: mdl-36230715
14.
Health-Related Quality of Life in Metastatic, Hormone-Sensitive Prostate Cancer: ENZAMET (ANZUP 1304), an International, Randomized Phase III Trial Led by ANZUP.
J Clin Oncol
; 40(8): 837-846, 2022 03 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34928708
15.
Evaluation of a Mainstream Model of Genetic Testing for Men With Prostate Cancer.
JCO Oncol Pract
; 17(2): e204-e216, 2021 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32970524
16.
Relationship between Circulating Lipids and Cytokines in Metastatic Castration-Resistant Prostate Cancer.
Cancers (Basel)
; 13(19)2021 Oct 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-34638448
17.
Overcoming enzalutamide resistance in metastatic prostate cancer by targeting sphingosine kinase.
EBioMedicine
; 72: 103625, 2021 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-34656931
18.
Overall Survival of Men with Metachronous Metastatic Hormone-sensitive Prostate Cancer Treated with Enzalutamide and Androgen Deprivation Therapy.
Eur Urol
; 80(3): 275-279, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34030924
19.
Effects of fibroblast growth factors on the differentiation of the pulmonary progenitors from murine embryonic stem cells.
Exp Lung Res
; 36(5): 307-20, 2010 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-20497026
20.
Extracellular Fatty Acids Are the Major Contributor to Lipid Synthesis in Prostate Cancer.
Mol Cancer Res
; 17(4): 949-962, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30647103